BiomX (PHGE)

Executive Summary

BiomX is a clinical-stage biotechnology company pioneering engineered bacteriophage therapies to precisely target and eliminate pathogenic bacteria driving chronic diseases, while preserving the beneficial microbiome. The company’s lead program targets adherent-invasive E. coli (AI-EC) in Crohn’s disease patients, addressing a significant unmet need where pathogenic bacteria are a known driver of disease. BiomX is also advancing a phage-based candidate for acne vulgaris and developing a therapy for colorectal cancer associated with Fusobacterium nucleatum. Utilizing a proprietary discovery and rational engineering platform, BiomX optimizes natural phages into defined cocktail formulations. The company is conducting clinical trials to evaluate safety and efficacy, with a focus on dermatology and gastroenterology indications where bacterial pathogens play a crucial role. As a public company on the NYSE American (PHGE), BiomX represents a novel approach to precision microbiome modulation, leveraging decades of phage biology research to create targeted therapeutics with potential for improved outcomes and reduced microbiome disruption compared to broad-spectrum antibiotics.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for Crohn’s disease (AI-EC)40% success
• Q4 2026Phase 2 results for acne vulgaris phage therapy35% success
• Q2 2026Early preclinical or IND enabling data for colorectal cancer candidate50% success